Patents by Inventor Martin A. Maier

Martin A. Maier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20210162053
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Application
    Filed: October 7, 2020
    Publication date: June 3, 2021
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10995336
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 4, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • TMPRSS6 iRNA compositions and methods of use thereof
    Patent number: 10988768
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 27, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin A. Maier, Klaus Charisse
  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210108203
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 15, 2021
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
    Patent number: 10934544
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 2, 2021
    Assignee: Alny lam Pharmaceuticals, Inc.
    Inventors: Akin Akinc, Gregory Hinkle, Martin A. Maier, James Butler, Jingxuan Liu
  • ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210046187
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Application
    Filed: September 15, 2020
    Publication date: February 18, 2021
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin A. Maier, Stuart Milstein
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10920223
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 16, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • TMPRSS6 iRNA compositions and methods of use thereof
    Patent number: 10913950
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 9, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin A. Maier, Klaus Charisse
  • MODIFIED DOUBLE-STRANDED RNA AGENTS
    Publication number: 20210017519
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2?-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 21, 2021
    Inventors: Martin MAIER, Don FOSTER, Stuart MILSTEIN, Satya KUCHIMANCHI, Vasant JADHAV, Kallanthottathil RAJEEV, Muthiah MANOHARAN, Rubina PARMAR
  • TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200392511
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 17, 2020
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin A. Maier, Klaus Charisse
  • TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
    Publication number: 20200377889
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
    Type: Application
    Filed: May 1, 2020
    Publication date: December 3, 2020
    Applicants: Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc.
    Inventors: Tracy Zimmermann, Amy Chan, Vasant R. Jadhav, Martin A. Maier, Kallanthottathil G. Rajeev
  • LIPID CONTAINING FORMULATIONS
    Publication number: 20200361854
    Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
    Type: Application
    Filed: December 13, 2019
    Publication date: November 19, 2020
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
  • MODIFIED RNAi AGENTS
    Publication number: 20200353097
    Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: April 16, 2020
    Publication date: November 12, 2020
    Inventors: Kallanthottathil G. RAJEEV, Tracy ZIMMERMANN, Muthiah MANOHARAN, Martin MAIER, Satyanarayana KUCHIMANCHI, Klaus CHARISSE
  • IMAGE PROCESSING DEVICE, IMAGE PROCESSING METHOD, AND IMAGE DISPLAY SYSTEM
    Publication number: 20200357357
    Abstract: An image processing device includes a memory that stores a program and a processor that executes the program stored in the memory to perform a process. The process includes obtaining input image data that is generated by combining, in a horizontal direction, an effective display area of first image data and an effective display area obtained by expanding an effective display area of second image data in the vertical direction, the vertical size of the second image data being smaller than the vertical size of the first image data; and generating second output image data corresponding to the second image data by reducing the vertical size of second intermediate image data among first intermediate image data and the second intermediate image data, which are obtained by dividing the input image data in the horizontal direction, based on the vertical size of the effective display area of the second image data.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 12, 2020
    Inventors: Nobutaka YAMAGISHI, Manuel RAJ-SALEH, Martin MAIER
  • TMPRSS6 iRNA compositions and methods of use thereof
    Patent number: 10829763
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: November 10, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Martin A. Maier, Kevin Fitzgerald, Shannon Fishman, Donald Foster, Vasant R. Jadhav, Stuart Milstein
  • Lipids and compositions for the delivery of therapeutics
    Patent number: 10821186
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: November 3, 2020
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200339991
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer disease (EOFAD or eFAD), using such dsRNAi agents and compositions.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Stuart Milstein, Kirk Brown, Jayaprakash Nair, Martin Maier, Vasant Jadhav, Mark Keating, Adam Castoreno, Patrick Haslett, Mangala Meenakshi Soundarapandian, Kevin Fitzgerald
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 10814007
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: October 27, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin A. Maier, Stuart Milstein
  • Carbohydrate conjugates as delivery agents for oligonucleotides
    Patent number: 10806791
    Abstract: The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 20, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash Nair, Martin Maier
  • RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
    Publication number: 20200318111
    Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
    Type: Application
    Filed: January 9, 2020
    Publication date: October 8, 2020
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin A. Maier, Satyanarayana Kuchimanchi, Klaus Charisse